Diabetes, obesity & metabolismJul 6, 2026

A molecule that first activates then blocks two hormone receptors leads to greater weight loss in obese mice

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 7, 2026

Abstract

Pharmacological agents targeting the GLP-1 and GIP receptors are promising for diabetes and obesity treatment.

GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists may effectively aid in weight management.
The specific impact of activating versus inhibiting the GIP receptor on weight loss is not yet understood.
Current therapies include Semaglutide, Tirzepatide, and AMG133, which show potential in managing diabetes and obesity.

Simplified

The GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) are key targets for diabetes and obesity therapies. Pharmacological agents including GLP-1R agonists (e.g., Semaglutide), dual GLP-1R/GIPR agonists (e.g., Tirzepatide) and a GLP-1R agonist/GIPR antagonist (AMG133) have demonstrated considerable promise in anti-diabetic and weight management applications. However, a systematic comparison of the specific contributions of GIPR activation versus GIPR inhibition to weight loss within the context of GLP-1/GIP dual-targeting therapies remains unexplored.

Full Text

Full text is available at the source.

View Full Text ↗

A molecule that first activates then blocks two hormone receptors leads to greater weight loss in obese mice

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief